FastDM1 Test has High Accuracy

A New test has been available in recent time to detect myotonic dystrophy. From Websites it looks as though this is labeled “For Research Only” A study attached shows that the test seems very accurate. And a figure on one of the web sites seems to indicate that it may be used for in vitro fertilization. there seems to be two type of kits one that gives an exact sizing when the repeats are less than 180 and another that detects over 180 repeats. When you click on the pictures of the test below it takes you to a related test which can give you an idea of what 

 
 

Myotonic Dystrophy 1 FASTDM1

Sales start during ESHG-Barcelona 2016!

Myotone Dystrophy Type 1 (DM1, Steinert Disease) is the most common form of muscular dystrophies by adults. In non-molecular testing methods for DM1, there is a risk of confusion due to overlapping symptoms with other neuromuscular diseases. A clear diagnosis is only possible molecular-genetic. TNR Diagnostics develops assays to detect the size of CTG Repeat expansions on the DMPK gene. Early diagnoses and associated symptom management can bring significant relief to affected patients.

Molecular genetic testing of the DMPK gene is necessary in individuals with suspected muscle weakness. Early diagnosis of DM1 patients would allow early intervention with medications for symptoms such as heart problems, diabetes mellitus and cataract.

Brochure to download here.

 

Change of landscape for muscular dystrophy testing

The FastDM1™ are a complete series of robust molecular diagnostic kits that meet the comprehensive testing requirements. Please click on the product image for more information about the various test kits .

 

DMPK Identification Kit DMPK Sizing Kit

Possible use for FastDM1™

The CTG repeat rate in the DMPK gene is responsible for muscle weakness in the affected individuals and causes a number of symptoms, such as cardiological problems, cataracts and diabetes mellitus. FastDM1™ DMPK analysis kits enable high-throughput sample processing without compromising sensitivity.

 

FastDM1-Diagnostic-Test-article

Genetic Testing best practices for Myotonic Dystrophy Patients

Because of the disease characteristics in DM1 and DM2, appropriate molecular testing and reporting is very important for the optimal counseling in myotonic dystrophy. Here, we describe best practice guidelinesfor clinical molecular genetic analysis and reporting in DM1 and DM2, including presymptomatic and prenatal testing.

New drug, Tideglusib, approach moving to clinical trial shortly

There is a new compound that is being tested to see if it can help with congenital myotonic dystrophy. It is being tested for a number of applications including tooth repair and Alzheimer’s  and just might help with the congenital form of myotonic dsytrophy. this is a molecule being developed by AMO pharma.

Tideglusib (NP-12NP031112) is a potent, selective and irreversible[1] small molecule non-ATP-competitive glycogen synthase kinase 3 (GSK-3) inhibitor.

Potential applications[edit]

Tideglusib is under investigation for multiple applications:

  • Alzheimer’s disease and progressive supranuclear palsy. As of 2017 it was undergoing Phase IIa[2] and IIb clinical trials.[3][4][5][6] The first trial to be published (in English) was Phase IIand demonstrated that tideglusib was well tolerated, except for some moderate, asymptomatic, fully reversible increases in liver enzymes.[4]
  • Tooth repair mechanisms that promotes dentine reinforcement of a sponge structure until the sponge biodegrades, leaving a solid dentine structure. In 2016, the results of animal studies were reported in which 0.14 mm holes in mouse teeth were permanently filled.[7]
  • Tideglusib is being studied in Phase II clinical trials as a treatment for congenital/juvenile-onset myotonic muscular dystrophy type I.[8]

There is a clinical study that will be starting shortly and you might be able to participate when this trial opens. Click here for more information.

https://clinicaltrials.gov/ct2/show/NCT03692312?cond=Myotonic+Dystrophy%2C+Congenital&rank=1

Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

Continue reading

Common Antibiotic Might Help Treat Myotonic Dystrophy Type 1 – Promising Therapy

Featured

In a study published in December 2015 in a peer review journal researchers from Japan and Poland found that a commonly used antibiotic might assist in the treatment of Myotonic Dystrophy. This is a sort of interesting  discovery as there is no treatment identified to treat the disease. Treatment now consists of reducing symptoms. There are several other approaches that are in development maybe as soon as the end of this year. Here is a link to another promising therapy as well Cagumycin

The researchers first began by screening antibiotics. In a screen of 20 antibiotics 2-3 were found to have some potential with the disease.When screening the drugs they first used mice cells and lab equipment to find the most promising compounds (drugs). . Erythromyicin was found to have the highest attraction to the RNA CUG expansion (The opposite of CTG repeats in the DNA) Erythromycin was the drug that the researchers chose to study. Click here for the screening graph Muscleblind and Various antibiotics and compounds

Continue reading

Patients even with short CTG repeats with Myotonic Dystrophy may have cardiac issues

A new case study has found that some patients with short DM repeats less than 100 who may not have symptoms of the disease may in fact be troubled with cardiac issues. Here is a full text of the study’s conclusions

This case shows that MD1 with <100 CTG repeats may
exclusively manifest cardiologically, that family screening
for MD1 is important even in asymptomatic patients, and
that MD1 may initially manifest with atypical clinical features.
Muscle biopsy in MD1 may be misleading and may
indicate glycogenosis. Close cardiac follow-up is important
if MD1 manifests cardiologically to prevent syncope or SCD.

 

Patients even with short repeats may have cardiac issues may 2015